Gmail **Elizabeth Hart <eliz.hart25@gmail.com>**

HPV vaccines and aluminium - Your complaints over maladministration at the EMA in relation to the safety of the HPV vaccines

Elizabeth Hart <eliz.hart25@gmail.com> Wed, Oct 12, 2016 at 10:48 PM
To: Tom Jefferson <jefferson.tom@gmail.com>
Cc: Peter Gøtzsche <pcg@cochrane.dk>, kj@cochrane.dk, margrete.auken@europarl.europa.eu, Louise.Schouborg.Brinth@regionh.dk

Dr Jefferson, re your and your colleagues' complaints over maladministration at the EMA in relation to the safety of the HPV vaccines (letters dated 26 May 2016 and 10 October 2016 and published on the Cochrane Nordic Research webpage: http://nordic.cochrane.org/research-highlights)

In your complaint letters you refer to the problematic use of a 'placebo' containing aluminium adjuvant in the HPV vaccine trials, and also note that aluminium adjuvant ***"is neurotoxic in high doses"*** (refer letter dated 10 October, p. 27).

In regards to the use of aluminium adjuvant in a placebo, I recently received an email from Professor Christopher Exley including his submitted Letter to the Editor of *The Lancet Infectious Diseases*, challenging a recently published paper concerning HPV safety, efficacy and immunogenicity in women over the age of 25[1], **and in which he argued the paper was missing vital information specifically in relation to safety, and questioning the use of aluminium hydroxide as a placebo for the control group**.

Professor Exley indicated I could forward his submitted letter to *The Lancet Infectious Diseases* to other interested parties (although the letter should not be posted online, pending approval/acceptance by *The Lancet Infectious Diseases*.)

As Professor Exley's letter is relevant to your complaints re the safety of HPV vaccines, I am forwarding it to you for your information, please see attached.

The paper which is the focus of Professor Exley's criticism is also attached for your information. It reports on the VIVIANE study, which was funded and coordinated by GlaxoSmithKline Biologicals. The Declaration of interests statement in this paper also indicates many authors of the paper are heavily associated with the vaccine industry.

Sincerely
Elizabeth Hart
https://over-vaccination.net/

Ref 1: Wheeler CM, Skinner SR, Del Rosario-Raymundo MR et al., Efficacy, safety and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. *Lancet Infect Dis* 2016; 16:1154-68

2 attachments

THELANCETID-S-16-01735.pdf
132K

1-s2.0-S1473309916301207-main.pdf
343K